Crossmark

Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer

Crossref DOI link: https://doi.org/10.1007/s40273-018-0752-0

Published Online: 2018-12-04

Published Print: 2019-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Min https://orcid.org/0000-0003-1960-4552
Pietanza, M. Catherine

Samkari, Ayman

Pellissier, James

Burke, Thomas

Chandwani, Sheenu

Kong, Fansen

Pickard, A. Simon
Funding

Funding for this research was provided by:

Merck
License Information

Text and Data Mining valid from 2018-12-04
More Information

Article History

First Online: 4 December 2018

Compliance with Ethical Standards

:

: This study and manuscript were funded by Merck & Co. Inc. MH, MCP, AS, JP, TB, SC and FK are employees of Merck & Co. Inc., the sponsor of this study and manuscript. ASP provides advisory and consultancy services to the EuroQol Group, Merck, Bristol-Myers Squibb, and Novartis.